共 157 条
[1]
Bao C(2014)Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial Rheumatology (Oxford, England) 53 1654-1663
[2]
Huang F(2012)Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study Ann Rheum Dis 71 661-667
[3]
Khan MA(2015)Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study Ann Rheum Dis 74 757-761
[4]
Fei K(2018)Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE Study J Rheumatol 45 341-348
[5]
Wu Z(2017)Golimumab: a review in inflammatory arthritis BioDrugs: Clin Immunother Biopharm Gene Therapy 31 263-274
[6]
Han C(2008)Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial Arthritis Rheum 58 3402-3412
[7]
Hsia EC(2015)Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis Ann Rheum Dis 74 538-546
[8]
Braun J(2018)Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis Rheumatol Int 38 2121-2131
[9]
Deodhar A(2017)The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis Zhonghua nei ke za zhi 56 935-939
[10]
Inman RD(2015)The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use Exp Rev Pharmacoeconomics Outcomes Res 15 851-858